FOS and pulmonary fibrosis: On the transcriptional level, KLF2 has been shown earlier to suppress pulmonary fibrosis and inflammation, and to strongly impede TGF-β signals in the endothelium, through the inhibition of the activator protein 1 (AP-1) (28, 29).